Skip to content

HESPERCO

The Hesperidin Coronavirus Study

HESPERCO: The Hesperidin Coronavirus Study

A randomized, double-blind, placebo-controlled study of hesperidin therapy on COVID-19 symptoms

Hesperidin to reduce the severity of illness and requirement for hospitalization

Highlights

HighlightsSummary of our HESPERCO research

7 Min

Source: Cytokine Storm in COVID-19 – Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches; The REPROGRAM Consortium Position Paper Frontiers in Immunology July 2020 | Volume 11 | Article 1648

Hesperidin & the modulation of inflammation and cytokine storm

The REPROGRAM Consortium Position Paper was prepared by an international not-for-profit think-tank for global pandemic preparedness and action.

The authors list what ideally a drug or a cocktail of drugs should be regulating to prevent or treat the exuberant inflammatory response – cytokine storm in COVID-19:

  • ↓ means down regulate or reduce
  • ↑ means upregulate or increase

Note how hesperidin has been reported to regulate these cytokines in experiments where severe inflammation was induced to affect the heart, lungs and brain.

For individuals who become symptomatic, the incubation period, the time from exposure to symptom onset, is 4–5 days on average with the most common symptoms including fever and cough.

Mild cases are likely characterized by a robust immune response, resulting in viral clearance.

For a minority of subjects, the disease worsens approximately 5–10 days after symptom onset, resulting in complications such as acute respiratory distress syndrome (ARDS) and other organ failure. In such severe cases, there is likely an initial delay in the antiviral response and subsequently increased production of inflammatory cytokines (cytokine storm syndrome).

HESPERCO: The Hesperidin Coronavirus Study

A randomized, double-blind, placebo-controlled study of hesperidin therapy on COVID-19 symptoms

Hesperidin to reduce the severity of illness and requirement for hospitalization

To know more about HESPERCO clinical trial, see summary below or click ‌here.

  • The pandemic is a noncontrolled infection / immunization / vaccination on a global scale with SARS-CoV-2 as the immunogen
  • As such the primary immune response plays a key role but more precisely the lag time within the primary immune response
  • Before and during the primary immune response, SARS-CoV-2 can proliferate, disseminate and cause severe inflammation or cytokine storm
  • From an exhaustive review of the scientific literature related to SARS of 2002-2004 and the recent abundance of literature published on SARS-COV-2 and COVID-19, scientific assumptions are:
  • Hesperidin could address COVID-19 by these mechanisms:
  • Reported/anticipated to reduce viral load
  • Reported/anticipated to modulate inflammatory mediators
  • Reduction of the severity of illness
  • Reduction of the requirement for hospitalization

2 independent mechanisms of action:

  • Reported/anticipated to prevent entry and replication of SARS-COV-2
  • Reported/anticipated to modulate inflammatory mediators as evidenced in various animal models:
    • Myocardial infarction, ventilator-induced acute lung injury, neuronal apoptosis, cognitive impairment and other inflammatory models.
  • Presented in 2 downloadable PowerPoint presentations: short (highlights) and long (comprehensive) versions (PDF) or viewed in narrative videos.

Learn more

From an exhaustive review of the scientific literature related to SARS of 2002-2004 and the recent abundance of literature published on SARS-COV-2 and COVID-19, there is a strong scientific rationale that Hesperidin could address COVID-19 via the following mechanisms:
  • Reported/anticipated to prevent entry and replication of SARS-COV-2
  • Reported/anticipated to modulate inflammatory mediators as evidenced in various animal models:
    • Myocardial infarction, ventilator-induced acute lung injury, neuronal apoptosis, cognitive impairment and other inflammatory models.

Other Development Activities

We also work on